Tuesday, 15 Oct 2019

Therapeutic Updates

Key Highlights From the SELECT-COMPARE Trial

In this video, Dr. Roy Fleischmann discusses data from the SELECT-COMPARE trial with RINVOQ™ (upadacitinib).

THE SCIENCE OF RINVOQ™ (UPADACITINIB)—A NEW JAK INHIBITOR

The US FDA has recently approved a new treatment for rheumatoid arthritis. This article features selected highlights from the prescribing information and study results of this treatment.

Contemporary Management of RA: Is an Inflection Point at Hand?

This video features Dr. Alvin Wells, Dr. Roy Fleischmann, and Dr. Vibeke Strand discussing the goals of contemporary RA therapy, including the patient perspective, and the future of RA management.

Biosimilars in Rheumatology

A first-of-its kind educational video series focusing on the “hot topics” in biosimilars from the perspective of leading Rheumatology experts. This educational series is presented by Sandoz, Inc.

Peering Inside the Cell: Intracellular Signaling in Rheumatoid Arthritis

Over the last several decades, researchers have identified a diverse array of immune cells, cytokines, and other inflammatory mediators as important contributors to the pathogenesis of rheumatoid arthritis (RA). While these numerous actors contribute to different pathological processes in RA, many are known to activate common intracellular signaling pathways.

Therapeutic Update: Rheumatoid Arthritis: Redefined

The RA Redefined video matrix aims to educate on the evolving understanding behind the pathophysiology of rheumatoid arthritis (RA), the role of autoantibodies and cytokines in the disease, and how T cells and B cells perpetuate RA.

Best of EULAR 2018

A video matrix of the best moments and findings from our coverage of EULAR 2018 in Amsterdam